Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

PubMed  Google Scholar 

Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022;17:362–87.

Article  PubMed  Google Scholar 

Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023;24:1206–18.

Article  PubMed  Google Scholar 

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11:39–51.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.

PubMed  Google Scholar 

Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5:620–30.

Article  PubMed  Google Scholar 

Garinet S, Wang P, Mansuet-Lupo A, Fournel L, Wislez M, Blons H. Updated Prognostic Factors in Localized NSCLC. Cancers (Basel) [Internet]. 2022;14. Available from: https://doi.org/10.3390/cancers14061400

Kahya Y, Marım F, Ömeroğlu Şimşek G, Karakuş HS, Başer Öncel S, Tor MM, et al. Update: The New 9 Edition TNM Classification for Lung Cancer Is Now in Use. Thorac Res Pract. 2026;27:47–56.

PubMed  Google Scholar 

Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol. 2021;7:1824–32.

Article  PubMed  PubMed Central  Google Scholar 

Liao S, Penney BC, Zhang H, Suzuki K, Pu Y. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer. Acad Radiol. 2012;19:69–77.

Article  PubMed  Google Scholar 

Lababede O, Meziane MA. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. Oncologist. 2018;23:844–8.

Article  PubMed  PubMed Central  Google Scholar 

Lababede O, Meziane M, Rice T. Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams. Chest. 2011;139:183–9.

Article  PubMed  Google Scholar 

Argentieri G, Valsecchi C, Petrella F, Jungblut L, Frauenfelder T, Del Grande F, et al. Implementation of the 9th TNM for lung cancer: practical insights for radiologists. Eur Radiol. 2025;35:4395–402.

Article  PubMed  PubMed Central  Google Scholar 

Ebner R, Sheikh GT, Brendel M, Ricke J, Cyran CC. ESR Essentials: staging and restaging with FDG-PET/CT in oncology-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging. Eur Radiol. 2025;35:1894–902.

Article  PubMed  Google Scholar 

Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27:683–7.

Article  CAS  PubMed  Google Scholar 

Hirata K, Tamaki N, Quantitative, FDG PET Assessment for Oncology Therapy. Cancers (Basel) [Internet]. 2021;13. Available from: https://doi.org/10.3390/cancers13040869

Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–4.

PubMed  Google Scholar 

Moon SH, Hyun SH, Choi JY. Prognostic significance of volume-based PET parameters in cancer patients. Korean J Radiol. 2013;14:1–12.

Article  PubMed  Google Scholar 

Lee P, Bazan JG, Lavori PW, Weerasuriya DK, Quon A, Le Q-T, et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer. 2012;13:52–8.

Article  PubMed  Google Scholar 

Ogliari FR, Jongbloed M, Vaes RDW, Houben RMA, van den Bartolomeo V, et al. Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study. Eur J Nucl Med Mol Imaging. 2026;53:1836–46.

Article  CAS  PubMed  Google Scholar 

Vanhove K, Mesotten L, Heylen M, Derwael R, Louis E, Adriaensens P, et al. Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer. Cancer Treat Res Commun. 2018;15:7–12.

PubMed  Google Scholar 

Ding C, Mao X, Li N, Huang M, Huang Z, Bao W, et al. Metabolic tumor volume derived from F-FDG PET/CT as a prognostic parameter for non-small cell lung cancer (NSCLC) patients. Hell J Nucl Med. 2022;25:63–70.

PubMed  Google Scholar 

Lausen B, Schumacher M. Maximally Selected Rank Statistics. 1990.

Frederick LG, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual. Springer Science & Business Media; 2002.

Yoo SW, Kim J, Chong A, Kwon S-Y, Min J-J, Song H-C, et al. Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer. Nucl Med Mol Imaging. 2012;46:286–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsim S, O’Dowd CA, Milroy R, Davidson S. Staging of non-small cell lung cancer (NSCLC): a review. Respir Med. 2010;104:1767–74.

Article  CAS  PubMed  Google Scholar 

Zhang H, Wroblewski K, Jiang Y, Penney BC, Appelbaum D, Simon CA, et al. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2015;89:43–9.

Article  PubMed  PubMed Central  Google Scholar 

Oliveira FRA, Santos A, de O Mda, CL, Toro IFC, de Souza TF, Amorim BJ, et al. The ratio between the whole-body and primary tumor burden, measured on F-FDG PET/CT studies, as a prognostic indicator in advanced non-small cell lung cancer. Radiol Bras. 2021;54:289–94.

Article  PubMed  PubMed Central  Google Scholar 

Brose A, Miederer I, König J, Gkika E, Sahlmann J, Schimek-Jasch T, et al. Prognostic value of metabolic tumor volume on [F]FDG PET/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer. Cancer Imaging. 2024;24:171.

Article  PubMed  PubMed Central  Google Scholar 

Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, Hawes SE, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res. 2007;13:3255–63.

Article  CAS  PubMed  Google Scholar 

Barquín M, Calvo V, García-García F, Nuñez B, Sánchez-Herrero E, Serna-Blasco R, et al. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. Cancer Epidemiol. 2020;67:101737.

Article  PubMed  Google Scholar 

Li Y, Noma T, Liang L, Weng W. Sex Differences in Overall Survival Among Patients with Non-Small-Cell Lung Cancer Across Clinical Stages: A Population-Based SEER Study. Healthcare (Basel). 2026;14:966. Available from: https://doi.org/10.3390/healthcare14070966

Giorlando MA, Gabay C, Mendoza LA, Mari E, Escorial C, Schnetter L, et al. 149P Gender differences in non-small cell lung cancer: A comparative analysis of European and Asian patients. J Thorac Oncol. 2023;18:S123.

Article  Google Scholar 

Keam B, Lee SJ, Kim TM, Paeng JC, Lee S-H, Kim D-W, et al. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. J Thorac Oncol. 2015;10:1189–94.

Article  CAS  PubMed  Google Scholar 

Hashimoto K, Kaira K, Imai H, Mouri A, Yamaguchi O, Kuji I, et al. Metabolic tumor volume on F-fluorodeoxyglucose uptake as prognostic marker for osimertinib in patients with non-small cell lung cancer harboring sensitive EGFR mutation. Transl Lung Cancer Res. 2025;14:5383–92.

Article  PubMed  PubMed Central  Google Scholar 

Yamaguchi O, Kaira K, Hashimoto K, Mouri A, Shiono A, Miura Y, et al. Tumor metabolic volume by F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50. Sci Rep. 2020;10:14990.

Article  PubMed  PubMed Central  Google Scholar 

Werner-Wasik M, Nelson AD, Choi W, Arai Y, Faulhaber PF, Kang P, et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys. 2012;82:1164–71.

Article  PubMed